Indiva Ltd
XTSX:NDVA

Watchlist Manager
Indiva Ltd Logo
Indiva Ltd
XTSX:NDVA
Watchlist
Price: 0.03 CAD Market Closed
Market Cap: 5.9m CAD

Relative Value

NDVA doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of NDVA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NDVA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
74
vs Industry
92
Median 3Y
0.2
Median 5Y
0.4
Industry
2.6
Forward
0.2
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.4
Industry
21.4
vs History
vs Industry
26
Median 3Y
-5.7
Median 5Y
-5.7
Industry
16.4
vs History
vs Industry
5
Median 3Y
-3.2
Median 5Y
-3.2
Industry
22.8
vs History
vs Industry
2
Median 3Y
-4.6
Median 5Y
2.5
Industry
2.2
vs History
68
vs Industry
83
Median 3Y
0.6
Median 5Y
0.9
Industry
2.9
Forward
0.7
vs History
47
vs Industry
70
Median 3Y
2
Median 5Y
2
Industry
5.5
vs History
vs Industry
Median 3Y
-14
Median 5Y
-7.8
Industry
13
vs History
vs Industry
Median 3Y
-13.3
Median 5Y
-7.4
Industry
16.5
vs History
vs Industry
10
Median 3Y
-21.8
Median 5Y
-6.9
Industry
15.6
vs History
vs Industry
3
Median 3Y
-13.9
Median 5Y
-6.6
Industry
18.7
vs History
53
vs Industry
51
Median 3Y
1.2
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

NDVA Competitors Multiples
Indiva Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Indiva Ltd
XTSX:NDVA
5.9m CAD 0.2 -1.3 -14 -13.3
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498.9B USD 5.4 19.9 16.2 21.1
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.9 30.2 108.3 158.6
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
264.8B USD 4.1 13.9 9.9 11.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.6 14.1 9.9 11.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
CA
Indiva Ltd
XTSX:NDVA
Average P/E: 24.3
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
3%
4.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Indiva Ltd
XTSX:NDVA
Average EV/EBITDA: 439.7
Negative Multiple: -14
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.3
10%
10.8
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Indiva Ltd
XTSX:NDVA
Average EV/EBIT: 1 883.3
Negative Multiple: -13.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5